ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.50K | 88.90K | 47.30K | 76.20K | 86.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.50K | 88.90K | 47.30K | 76.20K | 86.70K |
| Cost of Revenue | 37.60K | 48.80K | 146.30K | 79.10K | 36.90K |
| Gross Profit | 21.00K | 40.10K | -99.00K | -2.90K | 49.90K |
| SG&A Expenses | 1.29M | 1.34M | 1.29M | 1.48M | 1.76M |
| Depreciation & Amortization | 118.50K | 126.10K | 452.60K | 524.90K | 488.60K |
| Other Operating Expenses | 2.90K | 4.40K | 54.50K | 4.40K | 44.10K |
| Total Operating Expenses | 1.67M | 1.76M | 2.79M | 2.27M | 2.95M |
| Operating Income | -1.61M | -1.67M | -2.74M | -2.20M | -2.87M |
| Income Before Tax | -2.20M | -2.23M | -6.98M | -2.63M | -3.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.20M | -2.23M | -6.98M | -2.63M | -3.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.20M | -2.23M | -6.98M | -2.63M | -3.20M |
| EBIT | -1.61M | -1.67M | -2.74M | -2.20M | -2.87M |
| EBITDA | -1.49M | -1.55M | -2.59M | -1.67M | -2.38M |
| EPS Basic | -0.03 | -0.03 | -0.09 | -0.03 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 |
| EPS Diluted | -0.03 | -0.03 | -0.09 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 80.52M | 80.13M | 79.30M | 77.94M | 75.61M |
| Average Diluted Shares Outstanding | 80.52M | 80.13M | 79.30M | 77.94M | 75.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |